Methotrexate Toxicity from Unintentional Dosing Errors: Calls to a Poison Center and Death Descriptions

Thompson, James T.; Love, Jennifer S.; Hendrickson, Robert G.

doi:10.3122/jabfm.2021.06.210120

Cited by 7 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The commonest cause of acute MTX toxicity in literature was due to accidental drug overdose or due to erroneous dispensing of the drug. 12, 13 Though unintentional overdose is commonly described, data from a poison control centre in the United States reported up to 20% consumptions that were intentional. 13 Bebarta et al, describing another retrospective cohort of acute MTX overdoses, reported no mortality in their series of 63 patients, with none of them developing any of the major adverse events like bone marrow suppression or death; however, this may have been due to the lower mean dose of MTX of 24 mg in this cohort, as opposed to a mean dose of 114.6 mg in our cohort.…”

Section: Discussionmentioning

confidence: 99%

“…12, 13 Though unintentional overdose is commonly described, data from a poison control centre in the United States reported up to 20% consumptions that were intentional. 13 Bebarta et al, describing another retrospective cohort of acute MTX overdoses, reported no mortality in their series of 63 patients, with none of them developing any of the major adverse events like bone marrow suppression or death; however, this may have been due to the lower mean dose of MTX of 24 mg in this cohort, as opposed to a mean dose of 114.6 mg in our cohort. 14 A third retrospective series from the USA, described a small number of patients with acute MTX ingestion, where the maximum dose was ~13 mg and they reported no major adverse events.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Profile of Acute Methotrexate Toxicity in Rheumatic Diseases: A Series of 15 Cases

Mruthyunjaya,

Maikap,

Bhuyan

et al. 2024

Indian Journal of Rheumatology

View full text Add to dashboard Cite

Background: Methotrexate (MTX) at a dose of ≤25 mg/week is one of the most prescribed disease-modifying anti-rheumatic drugs (DMARDs) in a variety of rheumatic diseases. It can potentially cause life-threatening neutropenic sepsis, and acute renal and hepatotoxicity when taken inadvertently at high doses. We aim to analyse the clinical profile and risk factors of patients who presented with acute MTX toxicity. Methods: All patients presenting to the Rheumatology department with a history of inadvertent consumption of higher doses of MTX (>25 mg/week), from July 2021 to May 2023 were included. Additional data was extracted from hospital electronic medical health records. The clinical profile, risk factors, and outcome of patients with MTX toxicity were analysed. Results: The median age of the patients in our cohort was 52 IQR (40–62.5) years, with 80% females. The median cumulative dose of MTX was 120 mg (IQR 95–150). The reason for overdose in our cohort was medication error in comprehending once-weekly dosing. The most common major adverse event was neutropenia (80%). All our patients had stomatitis, with half of them having oral bleeding. Gastrointestinal adverse events like vomiting and diarrhoea were seen in 60% and 13% of the patients, respectively. Our cohort had two patients who succumbed to the complications due to neutropenic sepsis. The dose of MTX did not correlate with the severity of the disease or duration of hospital stay; however, the latter was significantly influenced by lower absolute neutrophil count (ANC). Conclusion: Acute MTX toxicity is one of the severe rheumatological emergencies and the toxicity profile includes haematological, gastrointestinal, hepatic, and renal adverse events. Severe neutropenia leading to sepsis can be fatal if not intervened early.

show abstract

Section: Discussionmentioning

confidence: 99%